Technical Analysis for CRNX - Crinetics Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
D 37.93 -2.57% -1.00
CRNX closed down 2.57 percent on Monday, March 18, 2024, on 1.12 times normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
3 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Down Down

Date Alert Name Type % Chg
Fell Below 50 DMA Bearish 0.00%
Stochastic Reached Oversold Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Crossed Above 50 DMA Bullish -2.57%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -2.57%
Pocket Pivot Bullish Swing Setup -2.57%
Inside Day Range Contraction -2.57%
Fell Below 20 DMA Bearish -0.73%
Fell Below 50 DMA Bearish -0.73%
New Downtrend Bearish -0.73%

   Recent Intraday Alerts

Alert Time
60 Minute Opening Range Breakout about 16 hours ago
50 DMA Support about 17 hours ago
Down 3% about 20 hours ago
50 DMA Resistance about 20 hours ago
Fell Below 50 DMA about 20 hours ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Crinetics Pharmaceuticals, Inc. Description

Crinetics Pharmaceuticals, Inc. is a clinical stage pharmaceutical company. The Company is focused on the discovery and development of drugs to treat specialty endocrine diseases and endocrine-related tumors. It develops a pipeline of oral nonpeptide chemical entities that target peptide G protein coupled receptors (GPCRs) for the treatment of endocrine diseases. The Company’s lead product candidate is CRN00808 developed for the treatment of acromegaly. It also develops two other product candidates CRN02481 for hyperinsulinemia, and CRN01941 for the treatment of neuroendocrine tumors. CRN02481 and CRN01941 are both oral nonpeptide somastatin receptors that are in the pre-clinical stages of development. The company also conducts research programs on developing nonpeptide products for the treatment of Cushing’s disease.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Disease Organ Systems Pancreatic Cancer Insulin Endocrine System Stage Pharmaceutical Chemical Entities Neuroendocrine Tumor Neuroendocrine Tumors Acromegaly Neuroendocrinology Endocrine Disease Endocrine Diseases

Is CRNX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 47.58
52 Week Low 15.23
Average Volume 691,470
200-Day Moving Average 28.42
50-Day Moving Average 38.48
20-Day Moving Average 40.45
10-Day Moving Average 40.91
Average True Range 2.23
RSI (14) 43.82
ADX 25.17
+DI 20.55
-DI 22.15
Chandelier Exit (Long, 3 ATRs) 40.90
Chandelier Exit (Short, 3 ATRs) 42.54
Upper Bollinger Bands 45.73
Lower Bollinger Band 35.16
Percent B (%b) 0.26
BandWidth 26.16
MACD Line 0.37
MACD Signal Line 0.98
MACD Histogram -0.6101
Fundamentals Value
Market Cap 2.53 Billion
Num Shares 66.8 Million
EPS -3.64
Price-to-Earnings (P/E) Ratio -10.42
Price-to-Sales 558.22
Price-to-Book 4.82
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 40.24
Resistance 3 (R3) 40.36 39.71 39.86
Resistance 2 (R2) 39.71 39.12 39.65 39.73
Resistance 1 (R1) 38.82 38.76 38.50 38.70 39.60
Pivot Point 38.17 38.17 38.01 38.11 38.17
Support 1 (S1) 37.28 37.58 36.96 37.16 36.26
Support 2 (S2) 36.63 37.22 36.57 36.13
Support 3 (S3) 35.74 36.63 36.01
Support 4 (S4) 35.62